阿夫凯泰对症状性非梗阻性肥厚型心肌病患者心脏结构与功能的影响
ACACIA-HCM 3期随机安慰剂对照试验的预设探索性分析,纳入517例症状性非梗阻性肥厚型心肌病患者,评估阿夫凯泰(5-20 mg,根据左心室射血分数滴定)对超声心动图指标的影响。36周时阿夫凯泰降低左心室射血分数并增加左心室容积,改善舒张功能指标,提示其获益超出左心室流出道梗阻降低的效应。
要点
- 阿夫凯泰36周降低左心室射血分数-4.6%(95%CI -5.5~-3.6,P<0.001)并增加左心室容积。
- 阿夫凯泰改善舒张功能指标,36周侧壁e'速度增加0.9 cm/s、室间隔e'增加0.7 cm/s(P均<0.001)。
- 阿夫凯泰36周改善三尖瓣反流峰值速度-10.4 cm/s(95%CI -19.9~-1.0,P=0.030),疗效持续至治疗结束。
核心结论
- 在非梗阻性肥厚型心肌病患者中,阿夫凯泰改善超声心动图舒张功能指标,其获益超出既往研究中左心室流出道梗阻降低的效应。
研究设计与样本
- ACACIA-HCM(NCT06081894)为3期随机、安慰剂对照试验的预设探索性分析,517例症状性非梗阻性肥厚型心肌病患者按1:1随机接受阿夫凯泰(5-20 mg,根据左心室射血分数滴定)或安慰剂治疗至72周。
- 采用线性回归模型评估36周(主要终点时间)和治疗结束时超声心动图指标变化,校正基线值、腔内梗阻和基线心房颤动。
主要发现
- 36周时阿夫凯泰较安慰剂降低左心室射血分数-4.6%(95%CI -5.5~-3.6,P<0.001)并增加左心室容积。
- 36周时阿夫凯泰较安慰剂改善侧壁e'速度0.9 cm/s(95%CI 0.6~1.2)和室间隔e'速度0.7 cm/s(95%CI 0.4~0.9),P均<0.001;治疗结束时分别改善0.9 cm/s(95%CI 0.5~1.2)和0.9 cm/s(95%CI 0.6~1.1),P均<0.001。
- 治疗结束时室间隔E/e'改善-1.4(95%CI -2.1~-0.6,P<0.001)。
- 36周时三尖瓣反流峰值速度改善-10.4 cm/s(95%CI -19.9~-1.0,P=0.030),疗效持续至治疗结束。
- 36周时左心房容积指数未显著改善-1.3(95%CI -2.6~0.04,P=0.06),更长治疗暴露后呈改善趋势-1.7(95%CI -3.2~-0.3,P=0.022)。
临床怎么用
- 对于症状性非梗阻性肥厚型心肌病患者,阿夫凯泰在滴定过程中可改善舒张功能指标,最早在滴定第2周显现。
- 用药期间需关注左心室射血分数下降(36周平均降低4.6%)及左心室容积增加,按方案根据射血分数进行剂量滴定。
局限性
- 本分析为预设探索性分析,超声心动图指标为次要/探索性终点。
- 左心房容积指数在36周未达统计学显著改善(P=0.06)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Aficamten significantly improved both functional capacity and patient-reported health status in patients with symptomatic nonobstructive hypertrophic cardiomyopathy in the phase 3 randomized, placebo-controlled ACACIA-HCM trial (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints in Adults with Non-Obstructive HCM; NCT06081894). Serial echocardiographic examinations may provide insights into the mechanisms underlying the therapeutic effect of aficamten in this prespecified exploratory analysis. METHODS: Symptomatic patients with nonobstructive hypertrophic cardiomyopathy were randomized 1:1 to receive aficamten (range, 5-20 mg, titration based on left ventricular [LV] ejection fraction) or placebo for up to 72 weeks (end of treatment). The effect of aficamten on echocardiographic measures at 36 weeks (time of primary end point) and end of treatment was assessed with linear regression models adjusted for baseline values, intracavity obstruction, and baseline atrial fibrillation. RESULTS: Among 517 participants (mean±SD: age, 55±16 years; 54% female, 75% White, 13% Asian), mean baseline LV ejection fraction was 68±4% with abnormal measures of diastolic function. Compared with placebo, aficamten decreased LV ejection fraction (-4.6% [-5.5, -3.6]; P<0.001) at 36 weeks and increased LV volumes. Aficamten improved measures of diastolic function, including lateral e' and septal e' velocities, at 36 weeks (0.9 cm/s [0.6, 1.2] and 0.7 cm/s [0.4, 0.9], respectively; P<0.001 for both) and at end of treatment (0.9 cm/s [0.5, 1.2] and 0.9 cm/s [0.6, 1.1], respectively; P<0.001 for both) and septal E/e' by end of treatment (-1.4 [-2.1, -0.6]; P<0.001, respectively). Peak tricuspid regurgitation velocity improved at 36 weeks (-10.4 cm/s [-19.9, -1.0]; P=0.030) with a sustained effect through end of treatment. Left atrial volume index did not significantly improve at 36 weeks (-1.3 [95% CI, -2.6, 0.04]; P=0.06) but showed a trend towards improvement with longer treatment exposure (-1.7 [-3.2, -0.3]; P=0.022). Aficamten demonstrated incremental improvements in measures of LV structure and function compared to placebo as doses were increased, with improvement in diastolic indices evident by week 2 of titration. CONCLUSIONS: In patients with nonobstructive hypertrophic cardiomyopathy, aficamten improved echocardiographic measures of diastolic function. These findings suggest that the benefits of aficamten extend beyond the effects of LV outflow tract gradient reduction observed in prior studies. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT06081894.
引用
- Hegde SM, Wang X, Bhatia A, et al. Effect of Aficamten on Cardiac Structure and Function in Patients With Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. Circulation. 2026. PMID: 42667274. doi:10.1161/CIRCULATIONAHA.126.082343
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。